<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR346.html">Part 346
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 346.50  Labeling of anorectal drug products.
                            </h3>
                            <p class="depth0">The labeling of the product contains the following information for  anorectal ingredients identified in Sec. Sec. 346.10, 346.12, 346.14,  346.16, 346.18, and 346.20, and for combinations of anorectal  ingredients identified in Sec. 346.22. Unless otherwise specified, the  labeling in this subpart is applicable to anorectal drug products for  both external and intrarectal use.</p><p class="depth1"><em>(a)</em> Statement of identity. The labeling of the product contains the  established name of the drug, if any, and identifies the product as  ``anorectal (hemorrhoidal),'' ``hemorrhoidal,'' ``hemorrhoidal  (anorectal) (insert dosage form, e.g., cream, lotion, or ointment).''</p><p class="depth1"><em>(b)</em> of  this section, as appropriate. Other truthful and nonmisleading  statements, describing only the   indications for use that have been established and listed in this  paragraph, may also be used, as provided in Sec. 330.1(c)(2) of this  chapter, subject to the provisions of section 502 of the Federal Food,  Drug, and Cosmetic Act (the act) relating to misbranding and the  prohibition in section 301(d) of the act against the introduction or  delivery for introduction into interstate commerce of unapproved new  drugs in violation of section 505(a) of the act.</p><p class="depth2"><em>(1)</em> (``For the temporary relief of,'' ``Gives temporary relief of,''  or ``Helps relieve the'') (As an option, select one or both of the  following: ``local'' or ``anorectal'') [select one or more of the  following: ``discomfort,'' ``itching,'' or ``itching and discomfort,''  followed by: ``in the perianal area'' or ``associated with'' (select one  or more of the following: ``hemorrhoids,'' ``anorectal disorders,''  ``inflamed hemorrhoidal tissues,'' ``anorectal inflammation,''  ``hemorrhoidal tissues,'' or ``piles (hemorrhoids).'')]</p><p class="depth2"><em>(2)</em> Additional indications. Indications applicable to each active  ingredient of the product may be combined to eliminate duplicative words  or phrases so that the resulting indication is clear and understandable.  In addition to the indication identified in paragraph (b)(1) of this  section, the labeling of the product intended for external or  intrarectal use may also contain the following indications, as  appropriate.</p><p class="depth3"><em>(i)</em> For products for external use only containing any ingredient  identified in Sec. 346.10. ``For the temporary relief of'' (select one  or more of the following: ``pain,'' ``soreness,'' or ``burning'').</p><p class="depth3"><em>(ii)</em> For products containing epinephrine or epinephrine  hydrochloride identified in Sec. 346.12 (b) and (c) for external use  only, and for products containing ephedrine sulfate or phenylephrine  hydrochloride identified in Sec. 346.12 (a) and (d).</p><p class="depth4"><em>(A)</em> ``Temporarily reduces the swelling associated with'' (select one  of the following: ``irritated hemorrhoidal tissue and other anorectal  disorders'' or ``irritation in hemorrhoids and other anorectal  disorders'').</p><p class="depth4"><em>(B)</em> ``Temporarily shrinks hemorrhoidal tissue.''</p><p class="depth3"><em>(iii)</em> For products for external use only containing glycerin  identified in Sec. 346.14(a)(3) and for products for external and/or  intrarectal use containing any protectant identified in Sec. 346.14(a)  (2), (4), (6) through (10), and (b) (1) through (4).</p><p class="depth4"><em>(A)</em> ``Temporarily forms a protective coating over inflamed tissues  to help prevent drying of tissues.''</p><p class="depth4"><em>(B)</em> ``Temporarily protects irritated areas.''</p><p class="depth4"><em>(C)</em> ``Temporarily relieves burning.''</p><p class="depth4"><em>(D)</em> ``Provides temporary relief from skin irritations.''</p><p class="depth4"><em>(E)</em> ``Temporarily provides a coating for relief of anorectal  discomforts.''</p><p class="depth4"><em>(F)</em> ``Temporarily protects the inflamed, irritated anorectal  surface'' (select one of the following: ``to help make bowel movements  less painful'' or ``from irritation and abrasion during bowel  movement'').</p><p class="depth4"><em>(G)</em> ``Temporarily protects inflamed perianal skin.''</p><p class="depth4"><em>(H)</em> ``Temporarily relieves the symptoms of perianal skin  irritation.''</p><p class="depth3"><em>(iv)</em> For products containing aluminum hydroxide gel identified in  Sec. 346.14(a)(1) and for products containing kaolin identified in  Sec. 346.14(a)(5). ``For the temporary relief of itching associated  with moist anorectal conditions.''</p><p class="depth3"><em>(v)</em> For products for external use only containing any analgesic,  anesthetic, and antipruritic identified in Sec. 346.16.</p><p class="depth4"><em>(A)</em> ``For the temporary relief of'' (select one or both of the  following: ``pain'' or ``burning'').</p><p class="depth4"><em>(B)</em> ``Can help distract from pain.''</p><p class="depth4"><em>(C)</em> ``May provide a cooling sensation.''</p><p class="depth3"><em>(vi)</em> For products for external use only containing witch hazel  identified in Sec. 346.18(b), and for products for external use and/or  intrarectal use containing calamine or zinc oxide identified in Sec.  346.18 (a) and (c).</p><p class="depth4"><em>(A)</em> ``Aids in protecting irritated anorectal areas.''</p><p class="depth4"><em>(B)</em> ``Temporary relief of'' (select one or both of the following:  ``irritation'' or ``burning'').</p><p class="depth3"><em>(vii)</em> For products for external use only containing any ingredient  identified in Sec. 346.20. The indication in paragraph (b)(1) of this  section applies.</p><p class="depth1"><em>(c)</em> Warnings. Warnings applicable to each active ingredient of the  product may be combined to eliminate duplicative words or phrases so  that the resulting warning is clear and understandable. The labeling of  the product   contains the following warnings under the heading ``Warnings'':</p><p class="depth2"><em>(1)</em> ``If condition worsens or does not improve within 7 days,  consult a doctor.''</p><p class="depth2"><em>(2)</em> ``Do not exceed the recommended daily dosage unless directed by  a doctor.''</p><p class="depth2"><em>(3)</em> ``In case of bleeding, consult a doctor promptly.''</p><p class="depth2"><em>(4)</em> For products for external use only. ``Do not put this product  into the rectum by using fingers or any mechanical device or  applicator.''</p><p class="depth2"><em>(5)</em> For products for intrarectal use to be used with a special  applicator such as a pile pipe or other mechanical device. ``Do not use  this product with an applicator if the introduction of the applicator  into the rectum causes additional pain. Consult a doctor promptly.''</p><p class="depth2"><em>(6)</em> For products for external use only containing any local  anesthetic identified in Sec. 346.10, menthol identified in Sec.  346.16(c), or resorcinol identified in Sec. 346.20(b). ``Certain  persons can develop allergic reactions to ingredients in this product.  If the symptom being treated does not subside or if redness, irritation,  swelling, pain, or other symptoms develop or increase, discontinue use  and consult a doctor.''</p><p class="depth2"><em>(7)</em> For products containing any vasoconstrictor identified in Sec.  346.12. </p><p class="depth3"><em>(i)</em> ``Do not use this product if you have heart disease, high  blood pressure, thyroid disease, diabetes, or difficulty in urination  due to enlargement of the prostate gland unless directed by a doctor.''</p><p class="depth3"><em>(ii)</em> ``Ask a doctor or pharmacist before use if you are [bullet] \1\  presently taking a prescription drug for high blood pressure or  depression.'' ---------------------------------------------------------------------------</p><p class="depth4">\1\ See Sec. 201.66(b)(4) of this chapter. ---------------------------------------------------------------------------</p><p class="depth3"><em>(iii)</em> For products containing ephedrine sulfate identified in Sec.  346.12(a). ``Some users of this product may experience nervousness,  tremor, sleeplessness, nausea, and loss of appetite. If these symptoms  persist or become worse, consult your doctor.''</p><p class="depth2"><em>(8)</em> For products containing aluminum hydroxide gel identified in  Sec. 346.14(a)(1) and for products containing kaolin identified in  Sec. 346.14(a)(5). ``Remove petrolatum or greasy ointment before using  this product because they interfere with the ability of this product to  adhere properly to the skin area.''</p><p class="depth2"><em>(9)</em> For products for external use only containing resorcinol  identified in Sec. 346.20(b). ``Do not use on open wounds near the  anus.''</p><p class="depth1"><em>(d)</em> Directions. Directions applicable to each active ingredient of  the product may be combined to eliminate duplicative words or phrases so  that the resulting information is clear and understandable. The labeling  of the product contains the following information under the heading  ``Directions'':</p><p class="depth2"><em>(1)</em> ``Adults: When practical, cleanse the affected area'' (select  one or both of the following: ``with mild soap and warm water and rinse  thoroughly'' or ``by patting or blotting with an appropriate cleansing  pad''). ``Gently dry by patting or blotting with toilet tissue or a soft  cloth before application of this product.'' [Other appropriate  directions in this section may be inserted here.] ``Children under 12  years of age: consult a doctor.''</p><p class="depth2"><em>(2)</em> For products for external use only. ``Apply externally to the  affected area'' (insert appropriate time interval of administration as  identified in paragraphs (d)(6), (7), (8), or (9) of this section).</p><p class="depth2"><em>(3)</em> For products for external use that are pads containing anorectal  ingredients. ``Gently apply to the affected area by patting and then  discard.''</p><p class="depth2"><em>(4)</em> For products for intrarectal use that are wrapped suppositories.  ``Remove wrapper before inserting into the rectum.''</p><p class="depth2"><em>(5)</em> For products for intrarectal use that are to be used with a  special applicator such as a pile pipe or other mechanical device. ``FOR  INTRARECTAL USE: Attach applicator to tube. Lubricate applicator well,  then gently insert applicator into the rectum.''</p><p class="depth2"><em>(6)</em> For products for external use only containing any of the local  anesthetics identified in Sec. 346.10; analgesics, anesthetics, and  antipruritics identified in Sec. 346.16; or alcloxa or resorcinol  identified in Sec. 346.20. Apply to the affected area up to 6 times  daily.</p><p class="depth3"><em>(i)</em> For products for external use only containing dibucaine or  dibucaine hydrochloride identified in Sec. 346.10 (c) and (d). Apply to  the affected area up to 3 or 4 times daily.</p><p class="depth3"><em>(ii)</em> For products for external use only containing pramoxine  hydrochloride identified in Sec. 346.10(g). Apply to the affected area  up to 5 times daily.</p><p class="depth2"><em>(7)</em> For products containing vasoconstrictors identified in Sec.  346.12. Apply to the affected area up to 4 times daily.</p><p class="depth2"><em>(8)</em> For products for external use only containing glycerin  identified in Sec. 346.14(a)(3) or witch hazel identified in Sec.  346.18(b), and for products for external and/or intrarectal use  containing any protectant identified in Sec. 346.14(a)(1), (2), (4),  (5), (6), (7), and (9), and (b)(1), (2), (3), and (4), or any astringent  identified in Sec. 346.18(a) and (c). Apply to the affected area up to  6 times daily or after each bowel movement.</p><p class="depth2"><em>(9)</em> For products containing petrolatum or white petrolatum  identified in Sec. 346.14(a)(8) and (10). Apply liberally to the  affected area as often as necessary.</p><p class="depth1"><em>(e)</em> The word ``physician'' may be substituted for the word  ``doctor'' in any of the labeling statements in this section.  [55 FR 31779, Aug. 3, 1990, as amended at 59 FR 28767, June 3, 1994; 64  FR 13295, Mar. 17, 1999]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ❤ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
